STOCKHOLM, SE / ACCESS Newswire / August 26, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(Nasdaq US:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the Pareto Securities 17th Annual Healthcare Conference in Stockholm.Location: Hotel At Six, Stockholm, SwedenFormat: Presentation and 1×1 meetingsPresentation Date and Time: Wednesday, September 2, 2026, 14:25-14:45 CESTParticipant: Hans Jeppsson, Chief Financial OfficerFor more information, please contact:Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.comAbout Vicore PharmaVicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.comAttachmentsVicore Pharma to Present at the Pareto Securities 17th Annual Healthcare ConferenceSOURCE: Vicore Pharma HoldingView the original press release on ACCESS Newswire
Vicore Pharma to Present at The Pareto Securities 17th Annual Healthcare Conference
STOCKHOLM, SE / ACCESS Newswire / August 26, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(Nasdaq US:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the Pareto Securities 17th Annual Healthcare Conference in Stockholm.Location: Hotel At Six, Stockholm, SwedenFormat: Presentation and 1×1 meetingsPresentation Date and Time: Wednesday, September 2, 2026, 14:25-14:45 CESTParticipant: Hans Jeppsson, Chief Financial OfficerFor more information, please contact:Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.comAbout Vicore PharmaVicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.comAttachmentsVicore Pharma to Present at the Pareto Securities 17th Annual Healthcare ConferenceSOURCE: Vicore Pharma HoldingView the original press release on ACCESS Newswire
